China’s National Medical Products Administration (NMPA) has released a long-term strategy titled “Implementation Opinions on AI + Drug Regulation.” This ambitious regulation aims to integrate AI across the full pharmaceutical regulatory lifecycle by 2035.
The roadmap defines two key milestones. First, by 2030, China aims to establish an integrated regulatory-AI system supported by foundational computing infrastructure, high-quality regulatory datasets, and early-stage AI tools. By 2035, the NMPA foresees a fully mature, intelligent, and independent AI regulatory ecosystem.
The initiative includes the development of specialized AI infrastructure, such as large language models focused on pharmaceuticals and intelligent government regulatory agents to support drug R&D, manufacturing, and post-marketing distribution.
With respect to clinical research, this regulation focuses on the standardization of clinical trial data, electronic record systems, and updated validation guidelines. In the manufacturing area, AI agents will analyze real-time data for certain high-risk products, such as vaccines and blood products, by processing surveillance images and videos. For distribution, the NMPA will use AI to improve end-to-end traceability systems.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.